2024 |
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2024 |
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice |
Review essay (rassegna critica) |
Vai |
2024 |
Reply to: “irLI or not irLI: That is the question” |
Lettera |
Vai |
2024 |
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies |
Articolo in rivista |
Vai |
2024 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours |
Articolo in rivista |
Vai |
2024 |
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment |
Articolo in rivista |
Vai |
2024 |
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab |
Articolo in rivista |
Vai |
2024 |
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis |
Articolo in rivista |
Vai |
2023 |
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis |
Articolo in rivista |
Vai |
2023 |
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study |
Articolo in rivista |
Vai |
2023 |
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs |
Articolo in rivista |
Vai |
2023 |
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon |
Nota o commento |
Vai |
2023 |
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept |
Review essay (rassegna critica) |
Vai |
2023 |
The price and value of therapeutic synergy in liver cancer |
Nota o commento |
Vai |
2023 |
Reply |
Lettera |
Vai |
2023 |
Expert opinion vs. meta-analysis: To be or not to be? |
Lettera |
Vai |
2023 |
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
2023 |
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
2022 |
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison |
Articolo in rivista |
Vai |
2022 |
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma |
Lettera |
Vai |
2022 |
Reply |
Lettera |
Vai |
2022 |
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints |
Articolo in rivista |
Vai |
2022 |
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC |
Articolo in rivista |
Vai |
2022 |
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation |
Articolo in rivista |
Vai |
2022 |
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals |
Articolo in rivista |
Vai |
2022 |
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib |
Articolo in rivista |
Vai |
2022 |
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD |
Articolo in rivista |
Vai |
2022 |
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data |
Articolo in rivista |
Vai |
2022 |
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data |
Articolo in rivista |
Vai |
2022 |
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model |
Articolo in rivista |
Vai |
2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Vai |
2022 |
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis |
Articolo in rivista |
Vai |
2022 |
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment |
Articolo in rivista |
Vai |
2022 |
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence |
Articolo in rivista |
Vai |
2021 |
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study |
Articolo in rivista |
Vai |
2021 |
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) |
Articolo in rivista |
Vai |
2021 |
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? |
Articolo in rivista |
Vai |
2021 |
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis |
Articolo in rivista |
Vai |
2021 |
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials |
Articolo in rivista |
Vai |
2021 |
Identification of clinical phenotypes and related survival in patients with large hccs |
Articolo in rivista |
Vai |
2021 |
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients |
Articolo in rivista |
Vai |
2021 |
Biliary complications after liver transplantation: current perspectives and future strategies |
Review essay (rassegna critica) |
Vai |
2021 |
Systemic therapies for hepatocellular carcinoma: The present and the future |
Articolo in rivista |
Vai |
2021 |
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
Articolo in rivista |
Vai |
2021 |
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 |
Articolo in rivista |
Vai |
2021 |
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients |
Articolo in rivista |
Vai |
2021 |
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study |
Articolo in rivista |
Vai |
2021 |
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy |
Articolo in rivista |
Vai |
2021 |
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use |
Articolo in rivista |
Vai |
2021 |
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
2020 |
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors |
Articolo in rivista |
Vai |
2020 |
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis |
Articolo in rivista |
Vai |
2020 |
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
2020 |
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib |
Articolo in rivista |
Vai |
2020 |
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib |
Articolo in rivista |
Vai |
2020 |
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis |
Articolo in rivista |
Vai |
2020 |
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
2020 |
Biochemical biomarkers of NAFLD/NASH |
Capitolo o Saggio |
Vai |
2020 |
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis |
Articolo in rivista |
Vai |
2020 |
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology |
Articolo in rivista |
Vai |
2019 |
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives |
Articolo in rivista |
Vai |
2019 |
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis |
Articolo in rivista |
Vai |
2019 |
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives |
Articolo in rivista |
Vai |
2019 |
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Articolo in rivista |
Vai |
2019 |
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Abstract in atti di convegno pubblicato in rivista |
Vai |
2019 |
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials |
Articolo in rivista |
Vai |
2018 |
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? |
Articolo in rivista |
Vai |
2018 |
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? |
Articolo in rivista |
Vai |
2018 |
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? |
Articolo in rivista |
Vai |